Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation

Imatinib can induce complete molecular remission (CMR) in relapse chronic myelogenous leukemia (CML) after allogeneic hematopoietic stem cell transplantation, but it is indefinite whether imatinib is required to maintain CMR. We retrospectively reviewed 37 relapse CML post-transplants treated with i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Hua, Xiong, Yiying, Sun, Jing, Zhang, Yu, Huang, Fen, Zhou, Hongsheng, Fan, Zhiping, Xu, Dan, Wei, Yongqiang, Dai, Min, Feng, Ru, Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688864/
https://www.ncbi.nlm.nih.gov/pubmed/23823695
http://dx.doi.org/10.1371/journal.pone.0065981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688864/
https://www.ncbi.nlm.nih.gov/pubmed/23823695
http://dx.doi.org/10.1371/journal.pone.0065981

Ejemplares similares